Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentA filing with the Massachusetts Health Policy Commission says Headspace parent OrangeDot proposes to be acquired by Sword Health for cash, with an effective date of Sept. 14. The transaction value was not disclosed, but the move aligns with Sword’s push beyond virtual physical therapy and into mental health.
Daniel ChoAug 26, 2026
Regulatory & PolicyTurkey’s Competition Board said Teva may have used practices aimed at making it more difficult for competitors to enter the market. The regulator did not name a specific drug, while a Teva spokesperson linked the matter to the earlier European Commission probe that resulted in a $503 million fine now under appeal.
Daniel ChoAug 26, 2026
Regulatory & PolicyBioSpace reported that experts see the FDA’s handling of Replimune’s advanced melanoma therapy and Capricor’s Duchenne muscular dystrophy filing as evidence that the agency is moving past the Makary-Prasad period. That does not amount to broad leniency: companies preparing submissions still face the same need to narrow interpretive gaps and align early with the agency.
Daniel ChoAug 24, 2026
Biotech InnovationThe paper argues that exploratory analysis in single-cell omics still relies too heavily on visualization methods that require tuning and can be made to match prior expectations. Bonsai’s pitch is different: no tunable parameters, explicit handling of noise and a tree representation intended to preserve high-dimensional distances while supporting downstream analysis through Bonsai-scout.
Daniel ChoAug 22, 2026
Healthcare InvestmentScribe raised an upsized $150 million and has climbed 43% from its first-day price of $21.50 to $31.05 by Wednesday’s close, compared with a 12% gain in the XBI over the last month. The company is heading into Phase 1 in Australia with STX-1150, a PCSK9-targeting epigenetic silencer that investors will begin to judge on interim patient data in the first half of next year.
Daniel ChoAug 20, 2026
Biotech InnovationA Cell Press Blue review assembled findings from 350 previously published papers to argue that protein restriction and amino acid restriction may support healthy aging. Experts interviewed by STAT said the paper does not establish a human longevity benefit and could create risk if older adults, sedentary people, or people taking GLP-1 weight loss medicines respond by cutting protein too far.
Daniel ChoAug 20, 2026
Regulatory & PolicyAccording to people contacted by investigators, the government is asking about Epic agreements that bar employees from joining a broad set of health care businesses and about practices that may make it harder for rival technology vendors to access data needed to serve shared customers. The inquiry may never lead to charges, but it arrives as private lawsuits and complaints about Epic’s conduct are accumulating around a company that handles records for 57% of inpatient hospital beds in America.
Daniel ChoAug 15, 2026
Biopharmaceutical IndustryZenbexus is approved for patients with multiple myeloma who have undergone at least one prior line of treatment, and STAT reported the clearance marks the debut of a new class of medicine for the blood cancer. For Bristol Myers Squibb, the approval arrives as older myeloma products continue to erode, making execution on pricing, uptake and confirmatory evidence commercially important.
Daniel ChoAug 14, 2026
Regulatory & PolicyThe University of Michigan’s Monitoring the Future survey found young adults’ nicotine vaping reached its highest level since the question was added in 2017, and cannabis use stayed near prior peaks. The report pairs those trends with continued declines in alcohol use and historically low cigarette smoking, creating a more mixed public-health picture than a single headline suggests.
Daniel ChoAug 13, 2026
Regulatory & PolicyThe Trump administration on Monday publicly re-entered vaccine policy after months of avoiding the topic for political reasons, according to STAT. The order presents a new "Gold Standard Childhood Vaccine Recommendations" schedule, ties the change to earlier court intervention, and directs further review of some of the president’s assertions even as experts and at least one Republican lawmaker criticized the lack of evidence behind them.
Daniel ChoAug 11, 2026
Healthcare InvestmentBlossomHill sold nearly 9.4 million shares at $16 and expects gross proceeds of $150 million, above an original $129.1 million target. Latigo’s offering rose to 19.2 million shares at $18 for expected proceeds of about $345.6 million, versus a previously targeted up to $285.2 million. The signal for investors is less about two debuts in isolation than about reopening appetite for clinical-stage biotech stories tied to clear capital deployment plans.
Daniel ChoAug 10, 2026
Regulatory & PolicyThe ACCESS pilot program—Medicare’s latest initiative to improve chronic care—illustrates both promise and pitfalls in federal healthcare innovation. While regulators seek industry input on artificial intelligence, a lack of transparency about provider participation presents a critical communication gap.
Daniel ChoAug 6, 2026